Higher Belly Fat Percentage Tied to Worse Outcomes for IBD Patients
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 2, 2023 -- For patients with inflammatory bowel disease (IBD), higher intra-abdominal visceral adipose tissue (IA-VAT) as a percentage of total body mass is associated with worse outcomes and may increase resistance to biologic drug therapy, according to a study published online July 25 in Gastroenterology.
Andres J. Yarur, M.D., from Cedars Sinai Medical Center in Los Angeles, and colleagues enrolled indivduals with active IBD initiating infliximab, vedolizumab, or ustekinumab and a healthy control group to examine the association between IA-VAT and response. The primary outcome was corticosteroid-free deep remission (SFDR) at weeks 14 to 16; secondary outcomes were SFDR and endoscopic remission at weeks 30 to 46. Data were included for 141 IBD patients and 51 healthy controls. Body composition parameters did not differ between the IBD and healthy control cohorts.
The researchers found that compared with patients with a lower IA-VAT percentage, those with a higher IA-VAT percentage were less likely to achieve SFDR or endoscopic remission. Significantly higher serum interleukin-6 and tumor necrosis factor at baseline were seen for nonresponders with high IA-VAT percentage compared with responders and patients with low IA-VAT percentage. When comparing high and low IA-VAT percentage groups, drug pharmacokinetics and microbiota diversity were similar.
"We found that higher visceral adiposity was associated with higher levels of proinflammatory cytokines, suggesting that fat tissue promotes inflammation, the opposite of what we want, and increases resistance to biologic drug therapy," coauthor Gil Y. Melmed, M.D., also from Cedars-Sinai, said in a statement. "More research is needed because we don't know whether lowering visceral fat or giving higher doses of the medications would improve drug efficacy."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Study IDs Risk Factors for Extraintestinal Manifestations of IBD
WEDNESDAY, April 17, 2024 -- Certain demographic, clinical, and genetic factors heighten the risk for extraintestinal manifestations (EIMs) with inflammatory bowel disease (IBD)...
Higher Vitamin D Levels Cut Bowel Resection Risk With IBD
WEDNESDAY, April 3, 2024 (HealthDay News) -- An increased serum level of 25-hydroxyvitamin D (25[OH]D) is independently associated with a lower risk for bowel resection with...
Top-Down Treatment Superior for Crohn Disease
TUESDAY, March 5, 2024 -- Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.